Skip to main content
Your session has expired. Reloading...

Doctor's Assessment Included

Every result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.

Autoimmune

Beta-2 Glycoprotein Screening

Beta-2 glycoprotein screening completes the antiphospholipid antibody panel, ensuring no APS case is missed through incomplete testing.

What It Measures

This test measures IgG and/or IgM antibodies against beta-2 glycoprotein I. B2GPI is considered the primary antigenic target in antiphospholipid syndrome.

Why It Matters

Anti-B2GPI antibodies may be the only positive marker in some APS patients. IgG anti-B2GPI is most strongly associated with thrombotic risk. Testing completes the antiphospholipid antibody profile.

When to Test

Testing could be indicated alongside anti-cardiolipin and lupus anticoagulant as part of complete APS evaluation, or when those tests are negative but clinical suspicion for APS remains.

Symptoms

Low Levels

A negative result is normal and does not require follow-up in the absence of clinical suspicion.

High Levels

Positive anti-B2GPI contributes to APS diagnosis when persistent and combined with clinical criteria (thrombosis or pregnancy morbidity).

Lifestyle Tips

If APS is confirmed through persistent antibody positivity, follow specialist guidance.

Frequently Asked Questions

Why test for B2GPI in addition to cardiolipin?
Some APS patients are positive only for anti-B2GPI. Testing all three criteria antibodies ensures comprehensive screening and prevents missed diagnoses.
Is B2GPI the actual target in APS?
Research suggests B2GPI is the primary antigenic target. Anti-cardiolipin antibodies are actually directed against B2GPI bound to cardiolipin rather than cardiolipin alone.
Can B2GPI antibodies disappear over time?
Rarely. Persistent positivity is characteristic of APS. Transient positivity can occur with infections and is excluded by the 12-week confirmation requirement.